Scientists have identified two  candidates for the treatment of deadly Middle East Respiratory Syndrome (MERS)  virus. the name of the two promising drugs candidates are-REGN3051 and REGN3048 which have shown ability to neutralise the MERS virus.

This research took place in collaboration with biopharmaceutical company Regeneron which is situated in New York.

Researchers had relied on Regeneron’s VelociGene technology, in which they  created partially humanised mice that can be infected with MERS. This partially humanised mouse model will help researchers further to boost their ability to study all the potential treatments.

This mice will help scientists to understand how the virus causes disease in people

About Middle East Respiratory Syndrome (MERS)

To know more about the MERS- Click on the following link-MERS